美股社区 personal page - To The Moon

美股社区

美股社区

No personal profile

402Follow

15Followers

1Topic

0Badge

2021-08-22

$ASML Holding NV(ASML)$great

2021-08-05

$ASML Holding NV(ASML)$??

2021-08-13

$ASML Holding NV(ASML)$???

2021-08-10

FB up up up

2021-07-24

Like

3 Stocks to Buy Whether or Not a Market Crash Is Near

2021-07-24

$ASML Holding NV(ASML)$???

2022-06-18

$ON Semiconductor(ON)$🤞🏻

2022-06-14

$Infineon Technologies AG(IFNNY)$[Strong]

2022-05-06

$ON Semiconductor(ON)$[Speechless]

2022-05-05

$NXP Semiconductors NV(NXPI)$[Miser]

2022-04-23

$ON Semiconductor(ON)$[What]

2022-04-19

$NXP Semiconductors NV(NXPI)$[Sad]

2022-04-14

$Taiwan Semiconductor Manufacturing(TSM)$👍🏻

2022-04-09

$Taiwan Semiconductor Manufacturing(TSM)$[Cry] [Cry]

2021-09-12

$NVIDIA Corp(NVDA)$moving upside?

2021-08-21

$ASML Holding NV(ASML)$???

2021-08-04

Fantastic

ASML: Strong Momentum Should Lead To Higher Revenue Expectations At Upcoming Investor Day

2021-07-24

Good

Facebook rose over 2%, reaching record high

2021-07-21

Good

4 Dow Stocks With 48% to 58% Upside, According to Wall Street

2022-05-26

$NXP Semiconductors NV(NXPI)$[Strong]

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3563679013796521,"uuid":"3563679013796521","gmtCreate":1600587588130,"gmtModify":1650040658757,"name":"美股社区","pinyin":"mgsqmeigushequ","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":15,"headSize":402,"tweetSize":225,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.04","exceedPercentage":"93.27%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.06","exceedPercentage":"93.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9996206578,"gmtCreate":1661171916196,"gmtModify":1676536466188,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9996206578","repostId":"2261559826","repostType":4,"repost":{"id":"2261559826","pubTimestamp":1661159108,"share":"https://www.laohu8.com/m/news/2261559826?lang=&edition=full","pubTime":"2022-08-22 17:05","market":"us","language":"en","title":"Ryan Cohen's Stock Sale Is No Problem for Bed Bath & Beyond's True Believers","url":"https://stock-news.laohu8.com/highlight/detail?id=2261559826","media":"The Wall Street Journal","summary":"Cohen’s ‘army is right behind him,’ as individual investors continued to cheer the stock on social-m","content":"<html><head></head><body><p>Cohen’s ‘army is right behind him,’ as individual investors continued to cheer the stock on social-media platforms despite its worst one-day pullback ever</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25c61a1a491d9a5324860c918ef5f8ca\" tg-width=\"860\" tg-height=\"573\" width=\"100%\" height=\"auto\"/><span>Billionaire investor Ryan Cohen triggered the selloff in Bed Bath &amp; Beyond’s shares last week.</span></p><p>A stupefying rally in Bed Bath &amp; Beyond Inc.&#39;s stock came skidding to a halt last week when one of the company&#39;s biggest shareholders cashed out.</p><p>Now, a crowd of individual investors say they are hoping to ride out the worst of the selloff.</p><p>Even as Bed Bath &amp; Beyond slumped Friday in its worst one-day pullback ever, individual investors continued to cheer the stock on social-media platforms like Reddit, Discord and Twitter. Many posted emojis of diamonds and hands -- internet shorthand for someone who holds steadfast to their investments even when there is rising pressure to sell. Others tagged their posts with &#34;HODL&#34;: hold on for dear life.</p><p>Their message to the world? We aren&#39;t giving up.</p><p>Wil Lobach, a 39-year-old investor from New Jersey, said he is hoping to use the selloff as a way to add to his Bed Bath &amp; Beyond holdings.</p><p>He owns more than 250 shares of the struggling retailer. Having scooped them up at an average price of around $6.50, he is still up about 70% on his initial investment. Bed Bath &amp; Beyond shares fell 41% Friday to $11.03.</p><p>Mr. Lobach said the volatility in the stock last week did little to scare him. He also owns stakes in meme stocks GameStop Corp. and AMC Entertainment Holdings Inc., both of which are also known for their wild swings.</p><p>&#34;I&#39;m proud of him,&#34; Mr. Lobach said of billionaire investor Ryan Cohen, whose sale of his stake triggered the selloff in Bed Bath &amp; Beyond&#39;s shares last week.</p><p>Cohen&#39;s &#34;army is right behind him,&#34; Mr. Lobach added, noting that he supports the sale and believes Mr. Cohen isn&#39;t done with Bed Bath &amp; Beyond yet. &#34;It&#39;s been incredible to be a part of this moment in history.&#34;</p><p><img src=\"https://static.tigerbbs.com/cd01727ed0b3bfffe195bc48b96c1710\" tg-width=\"992\" tg-height=\"704\" width=\"100%\" height=\"auto\"/></p><p>Mr. Cohen, the co-founder of pet-supply retailer Chewy Inc., has developed a devoted following of individual investors, who cheered his rapid ascension last year from activist investor to GameStop chairman. Many individuals piled into Bed Bath &amp; Beyond&#39;s shares after he revealed a sizable stake in the company in March and issued a letter to its board pushing for major changes.</p><p>David Simpson, a 30-year-old from Seattle, said he is committed to holding on to his Bed Bath &amp; Beyond investment until at least 2023, by which time he believes the stock will have risen to around $200.</p><p>He wasn&#39;t deterred by news of Mr. Cohen selling his stake. In fact, he says his conviction in his Bed Bath &amp; Beyond trade has only gotten stronger. He referenced Mr. Cohen&#39;s role in Chewy&#39;s growth from a small startup into a company that would later be acquired by PetSmart for $3.35 billion, a deal that was at the time the biggest e-commerce acquisition ever.</p><p>&#34;My instincts tell me the same is true&#34; for Bed Bath &amp; Beyond, Mr. Simpson said, adding that he believes the company will be able to strengthen its financial position by the end of the year.</p><p>Bed Bath &amp; Beyond is searching for a $375 million loan to build cash and help pay down debt, The Wall Street Journal previously reported. In June, the company said sales for the current quarter were trending down 20% from the year-earlier period.</p><p><img src=\"https://static.tigerbbs.com/657ef9cdee72a0a7845b77f3777c118a\" tg-width=\"445\" tg-height=\"691\" width=\"100%\" height=\"auto\"/></p><p>Individual investors&#39; resolve is the latest twist in a meme-stock mania that has endured much longer than many professional investors and analysts could have ever predicted. Some individual investors say they have good reason to believe the shares will spike again.</p><p>Many are also continuing to hold out for what they believe will be a massive short squeeze, a phenomenon that occurs when a stock rises so much that investors who bet against it are forced to buy back shares, driving the stock even higher.</p><p>At the moment, those betting on the stock face an uphill battle.</p><p>On Friday, the selloff hitting Bed Bath &amp; Beyond spread to other meme stocks, with GameStop losing 3.8%, AMC Entertainment falling 6.6% and Coinbase Global Inc. shedding 11%. The S&amp;P 500 finished down 1.3%.</p><p>Data also show pressure from short sellers has continued to grow.</p><p>Roughly half of Bed Bath &amp; Beyond&#39;s shares that were available to trade Friday afternoon were being shorted, according to Ihor Dusaniwsky, head of predictive analytics at S3 Partners, a technology and data analytics firm.</p><p><img src=\"https://static.tigerbbs.com/a65f0cd9592adcecfe576cd8076066dc\" tg-width=\"437\" tg-height=\"630\" width=\"100%\" height=\"auto\"/></p><p>&#34;This has been a roller-coaster week,&#34; Mr. Dusaniwsky said in an email, noting the value of short sellers&#39; positions was down hundreds of millions of dollars in the first half of the week, only to jump hundreds of millions of dollars on Thursday and Friday.</p><p>Wall Street analysts are also warning there could be more pain ahead for shareholders.</p><p>Wedbush Securities analyst Seth Basham said he believes Bed Bath &amp; Beyond&#39;s stock should be trading at around $5 -- 55% below where it closed Friday. He cut his rating for the stock to &#34;underperform&#34; from &#34;neutral&#34; in a note after Mr. Cohen made his plans to sell his stake public Wednesday.</p><p>Even if the company manages to achieve goals like fixing its inventory and supply-chain problems, its stock has surged so much that the risk-to-reward ratio for investors remains &#34;disproportionately skewed to the downside,&#34; Mr. Basham added.</p><p>Bed Bath &amp; Beyond shares are still up 122% for the quarter, compared with the S&amp;P 500, which has risen 12%.</p><p>Wells Fargo analyst Zachary Fadem, who covers Bed Bath &amp; Beyond, is holding a price target of $3 for the stock -- 73% below where it closed Friday.</p><p>Among Mr. Fadem&#39;s concerns: Foot traffic at Bed Bath &amp; Beyond&#39;s stores and web traffic on its site seem to be decelerating. The company is also in a financially vulnerable position. It is working with external advisers to try to strengthen its balance sheet.</p><p>&#34;We believe the writing is on the wall that BBBY shares have again decoupled from economic reality,&#34; Mr. Fadem said in a note.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ryan Cohen's Stock Sale Is No Problem for Bed Bath & Beyond's True Believers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRyan Cohen's Stock Sale Is No Problem for Bed Bath & Beyond's True Believers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-22 17:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/ryan-cohens-stock-sale-is-no-problem-for-bed-bath-beyonds-true-believers-11661022516?mod=hp_lead_pos3><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cohen’s ‘army is right behind him,’ as individual investors continued to cheer the stock on social-media platforms despite its worst one-day pullback everBillionaire investor Ryan Cohen triggered the ...</p>\n\n<a href=\"https://www.wsj.com/articles/ryan-cohens-stock-sale-is-no-problem-for-bed-bath-beyonds-true-believers-11661022516?mod=hp_lead_pos3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BBBY":"3B家居"},"source_url":"https://www.wsj.com/articles/ryan-cohens-stock-sale-is-no-problem-for-bed-bath-beyonds-true-believers-11661022516?mod=hp_lead_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2261559826","content_text":"Cohen’s ‘army is right behind him,’ as individual investors continued to cheer the stock on social-media platforms despite its worst one-day pullback everBillionaire investor Ryan Cohen triggered the selloff in Bed Bath & Beyond’s shares last week.A stupefying rally in Bed Bath & Beyond Inc.'s stock came skidding to a halt last week when one of the company's biggest shareholders cashed out.Now, a crowd of individual investors say they are hoping to ride out the worst of the selloff.Even as Bed Bath & Beyond slumped Friday in its worst one-day pullback ever, individual investors continued to cheer the stock on social-media platforms like Reddit, Discord and Twitter. Many posted emojis of diamonds and hands -- internet shorthand for someone who holds steadfast to their investments even when there is rising pressure to sell. Others tagged their posts with \"HODL\": hold on for dear life.Their message to the world? We aren't giving up.Wil Lobach, a 39-year-old investor from New Jersey, said he is hoping to use the selloff as a way to add to his Bed Bath & Beyond holdings.He owns more than 250 shares of the struggling retailer. Having scooped them up at an average price of around $6.50, he is still up about 70% on his initial investment. Bed Bath & Beyond shares fell 41% Friday to $11.03.Mr. Lobach said the volatility in the stock last week did little to scare him. He also owns stakes in meme stocks GameStop Corp. and AMC Entertainment Holdings Inc., both of which are also known for their wild swings.\"I'm proud of him,\" Mr. Lobach said of billionaire investor Ryan Cohen, whose sale of his stake triggered the selloff in Bed Bath & Beyond's shares last week.Cohen's \"army is right behind him,\" Mr. Lobach added, noting that he supports the sale and believes Mr. Cohen isn't done with Bed Bath & Beyond yet. \"It's been incredible to be a part of this moment in history.\"Mr. Cohen, the co-founder of pet-supply retailer Chewy Inc., has developed a devoted following of individual investors, who cheered his rapid ascension last year from activist investor to GameStop chairman. Many individuals piled into Bed Bath & Beyond's shares after he revealed a sizable stake in the company in March and issued a letter to its board pushing for major changes.David Simpson, a 30-year-old from Seattle, said he is committed to holding on to his Bed Bath & Beyond investment until at least 2023, by which time he believes the stock will have risen to around $200.He wasn't deterred by news of Mr. Cohen selling his stake. In fact, he says his conviction in his Bed Bath & Beyond trade has only gotten stronger. He referenced Mr. Cohen's role in Chewy's growth from a small startup into a company that would later be acquired by PetSmart for $3.35 billion, a deal that was at the time the biggest e-commerce acquisition ever.\"My instincts tell me the same is true\" for Bed Bath & Beyond, Mr. Simpson said, adding that he believes the company will be able to strengthen its financial position by the end of the year.Bed Bath & Beyond is searching for a $375 million loan to build cash and help pay down debt, The Wall Street Journal previously reported. In June, the company said sales for the current quarter were trending down 20% from the year-earlier period.Individual investors' resolve is the latest twist in a meme-stock mania that has endured much longer than many professional investors and analysts could have ever predicted. Some individual investors say they have good reason to believe the shares will spike again.Many are also continuing to hold out for what they believe will be a massive short squeeze, a phenomenon that occurs when a stock rises so much that investors who bet against it are forced to buy back shares, driving the stock even higher.At the moment, those betting on the stock face an uphill battle.On Friday, the selloff hitting Bed Bath & Beyond spread to other meme stocks, with GameStop losing 3.8%, AMC Entertainment falling 6.6% and Coinbase Global Inc. shedding 11%. The S&P 500 finished down 1.3%.Data also show pressure from short sellers has continued to grow.Roughly half of Bed Bath & Beyond's shares that were available to trade Friday afternoon were being shorted, according to Ihor Dusaniwsky, head of predictive analytics at S3 Partners, a technology and data analytics firm.\"This has been a roller-coaster week,\" Mr. Dusaniwsky said in an email, noting the value of short sellers' positions was down hundreds of millions of dollars in the first half of the week, only to jump hundreds of millions of dollars on Thursday and Friday.Wall Street analysts are also warning there could be more pain ahead for shareholders.Wedbush Securities analyst Seth Basham said he believes Bed Bath & Beyond's stock should be trading at around $5 -- 55% below where it closed Friday. He cut his rating for the stock to \"underperform\" from \"neutral\" in a note after Mr. Cohen made his plans to sell his stake public Wednesday.Even if the company manages to achieve goals like fixing its inventory and supply-chain problems, its stock has surged so much that the risk-to-reward ratio for investors remains \"disproportionately skewed to the downside,\" Mr. Basham added.Bed Bath & Beyond shares are still up 122% for the quarter, compared with the S&P 500, which has risen 12%.Wells Fargo analyst Zachary Fadem, who covers Bed Bath & Beyond, is holding a price target of $3 for the stock -- 73% below where it closed Friday.Among Mr. Fadem's concerns: Foot traffic at Bed Bath & Beyond's stores and web traffic on its site seem to be decelerating. The company is also in a financially vulnerable position. It is working with external advisers to try to strengthen its balance sheet.\"We believe the writing is on the wall that BBBY shares have again decoupled from economic reality,\" Mr. Fadem said in a note.","news_type":1},"isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9043430002,"gmtCreate":1655949509106,"gmtModify":1676535738608,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/IIVI\">$II-VI Inc(IIVI)$</a>[Strong]&nbsp;","listText":"<a href=\"https://ttm.financial/S/IIVI\">$II-VI Inc(IIVI)$</a>[Strong]&nbsp;","text":"$II-VI Inc(IIVI)$[Strong]","images":[{"img":"https://community-static.tradeup.com/news/f1e655fab44291df9f9048a9ce07f1d9","width":"750","height":"1889"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9043430002","isVote":1,"tweetType":1,"viewCount":388,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9043495990,"gmtCreate":1655949283411,"gmtModify":1676535738539,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>[Observation]&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>[Observation]&nbsp;","text":"$Apple(AAPL)$[Observation]","images":[{"img":"https://community-static.tradeup.com/news/061624bac96f322d582028c2f893ad88","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9043495990","isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9043134763,"gmtCreate":1655885673752,"gmtModify":1676535725975,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/EDAP\">$Edap TMS SA(EDAP)$</a>[Put]&nbsp;","listText":"<a href=\"https://ttm.financial/S/EDAP\">$Edap TMS SA(EDAP)$</a>[Put]&nbsp;","text":"$Edap TMS SA(EDAP)$[Put]","images":[{"img":"https://community-static.tradeup.com/news/2db125d4bb5cf6c51bcc6030894fc78d","width":"750","height":"1799"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9043134763","isVote":1,"tweetType":1,"viewCount":425,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9043134813,"gmtCreate":1655885634632,"gmtModify":1676535725966,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>[Put]&nbsp;[Put]&nbsp;[Put]&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>[Put]&nbsp;[Put]&nbsp;[Put]&nbsp;","text":"$Apple(AAPL)$[Put] [Put] [Put]","images":[{"img":"https://community-static.tradeup.com/news/30823eb88df8cfeeb7a801ac02dc4a74","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9043134813","isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9049431950,"gmtCreate":1655824192770,"gmtModify":1676535712499,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/EDAP\">$Edap TMS SA(EDAP)$</a>[Miser]&nbsp;","listText":"<a href=\"https://ttm.financial/S/EDAP\">$Edap TMS SA(EDAP)$</a>[Miser]&nbsp;","text":"$Edap TMS SA(EDAP)$[Miser]","images":[{"img":"https://community-static.tradeup.com/news/34d12ea53d31a27884c7c89eb77cf6b1","width":"750","height":"1879"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049431950","isVote":1,"tweetType":1,"viewCount":320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9049433767,"gmtCreate":1655824183560,"gmtModify":1676535712499,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/EDAP\">$Edap TMS SA(EDAP)$</a>[Miser]&nbsp;","listText":"<a href=\"https://ttm.financial/S/EDAP\">$Edap TMS SA(EDAP)$</a>[Miser]&nbsp;","text":"$Edap TMS SA(EDAP)$[Miser]","images":[{"img":"https://community-static.tradeup.com/news/7e5f7af6ba4a4c8b474eafab02ab6e75","width":"750","height":"1879"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049433767","isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9057171558,"gmtCreate":1655483311474,"gmtModify":1676535649074,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>🤞🏻","listText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>🤞🏻","text":"$ON Semiconductor(ON)$🤞🏻","images":[{"img":"https://community-static.tradeup.com/news/1c00c211013e3be3ffc0f0a3fc3b3191","width":"1080","height":"4065"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9057171558","isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9054582779,"gmtCreate":1655417334891,"gmtModify":1676535632219,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[Cry]&nbsp;","listText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[Cry]&nbsp;","text":"$ON Semiconductor(ON)$[Cry]","images":[{"img":"https://community-static.tradeup.com/news/3a4478dcbbff49e1ec6d23aeb0a7e265","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9054582779","isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9054582356,"gmtCreate":1655417286575,"gmtModify":1676535632196,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/IIVI\">$II-VI Inc(IIVI)$</a>[Cry]&nbsp;","listText":"<a href=\"https://ttm.financial/S/IIVI\">$II-VI Inc(IIVI)$</a>[Cry]&nbsp;","text":"$II-VI Inc(IIVI)$[Cry]","images":[{"img":"https://community-static.tradeup.com/news/9bec98cf1bdfc77f3b658c9ea912b5e7","width":"750","height":"2069"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9054582356","isVote":1,"tweetType":1,"viewCount":331,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9055452429,"gmtCreate":1655305304861,"gmtModify":1676535609071,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[Miser]&nbsp;","listText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[Miser]&nbsp;","text":"$ON Semiconductor(ON)$[Miser]","images":[{"img":"https://community-static.tradeup.com/news/0a07a25479457c02781c2a0160aafcdb","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9055452429","isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9055456716,"gmtCreate":1655305249135,"gmtModify":1676535609032,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[Strong]&nbsp;","listText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[Strong]&nbsp;","text":"$ON Semiconductor(ON)$[Strong]","images":[{"img":"https://community-static.tradeup.com/news/07b108af2f832d9ae935bf847185925d","width":"750","height":"1879"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9055456716","isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9055031819,"gmtCreate":1655217013931,"gmtModify":1676535586476,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[Strong]&nbsp;","listText":"[Strong]&nbsp;","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9055031819","repostId":"9022524674","repostType":1,"repost":{"id":9022524674,"gmtCreate":1653552819200,"gmtModify":1676535303082,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Time Travel with Tiger, Join the Memorabilia Adventure Now!!!","htmlText":"\n \n \n  Happy Birthday to TIGER!!! This year, we have prepared a time machine to go on an adventure with you. Come and find surprising gifts as we stroll down memory lane!There are so many wonderful little stories in our Tiger Quest. Collect as many coins as you can in the game, these will be your basic points of this game. Apart from one mini-game mission for SG/AU/NZ, the games will be open every week, and there are endless treasures waiting for you to discover. Points can be redeemed for multiple rewards, and you can win a share of up to USD 200,000 worth of prizes! Want to win extra points? Check out these mini-games, try them, stay with us and be PAWSITIVE!Remember to collect the cards and spell out \"T.I.G.E.R\" during your journey for a chance to receive the limited edition 8th Anniversary Gi\n \n","listText":"Happy Birthday to TIGER!!! This year, we have prepared a time machine to go on an adventure with you. Come and find surprising gifts as we stroll down memory lane!There are so many wonderful little stories in our Tiger Quest. Collect as many coins as you can in the game, these will be your basic points of this game. Apart from one mini-game mission for SG/AU/NZ, the games will be open every week, and there are endless treasures waiting for you to discover. Points can be redeemed for multiple rewards, and you can win a share of up to USD 200,000 worth of prizes! Want to win extra points? Check out these mini-games, try them, stay with us and be PAWSITIVE!Remember to collect the cards and spell out \"T.I.G.E.R\" during your journey for a chance to receive the limited edition 8th Anniversary Gi","text":"Happy Birthday to TIGER!!! This year, we have prepared a time machine to go on an adventure with you. Come and find surprising gifts as we stroll down memory lane!There are so many wonderful little stories in our Tiger Quest. Collect as many coins as you can in the game, these will be your basic points of this game. Apart from one mini-game mission for SG/AU/NZ, the games will be open every week, and there are endless treasures waiting for you to discover. Points can be redeemed for multiple rewards, and you can win a share of up to USD 200,000 worth of prizes! Want to win extra points? Check out these mini-games, try them, stay with us and be PAWSITIVE!Remember to collect the cards and spell out \"T.I.G.E.R\" during your journey for a chance to receive the limited edition 8th Anniversary Gi","images":[],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9022524674","isVote":1,"tweetType":2,"object":{"id":"97af7069aa6440eab7c85601f72b41b1","tweetId":"9022524674","videoUrl":"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/5836ee3f387702302012189230/1IRQdazMc4YA.mp4","poster":"https://community-static.tradeup.com/news/f2462b20b2a9a2483ae56cbb54dcb2a7"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":46,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9055002161,"gmtCreate":1655216221253,"gmtModify":1676535586014,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/IFNNY\">$Infineon Technologies AG(IFNNY)$</a>[Strong]&nbsp;","listText":"<a href=\"https://ttm.financial/S/IFNNY\">$Infineon Technologies AG(IFNNY)$</a>[Strong]&nbsp;","text":"$Infineon Technologies AG(IFNNY)$[Strong]","images":[{"img":"https://community-static.tradeup.com/news/20347add9528c52df4684ffaa759062c","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9055002161","isVote":1,"tweetType":1,"viewCount":109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9025826700,"gmtCreate":1653660768400,"gmtModify":1676535322879,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[Miser]&nbsp;","listText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[Miser]&nbsp;","text":"$ON Semiconductor(ON)$[Miser]","images":[{"img":"https://community-static.tradeup.com/news/ad4945c18382c79e98aff86d71267e5d","width":"750","height":"1819"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9025826700","isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9022257989,"gmtCreate":1653535354041,"gmtModify":1676535300552,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Strong]&nbsp;","listText":"<a href=\"https://ttm.financial/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Strong]&nbsp;","text":"$NXP Semiconductors NV(NXPI)$[Strong]","images":[{"img":"https://community-static.tradeup.com/news/a250be0f17514cd6088b7266cca77b6f","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9022257989","isVote":1,"tweetType":1,"viewCount":200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9022254868,"gmtCreate":1653535181654,"gmtModify":1676535300528,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9022254868","repostId":"2238472135","repostType":4,"repost":{"id":"2238472135","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1653528977,"share":"https://www.laohu8.com/m/news/2238472135?lang=&edition=full","pubTime":"2022-05-26 09:36","market":"us","language":"en","title":"Walmart, CVS Will Stop Filling Controlled-Substance Prescriptions for Cerebral","url":"https://stock-news.laohu8.com/highlight/detail?id=2238472135","media":"Dow Jones","summary":"CVS Health Corp. and Walmart Inc. will stop filling prescriptions for controlled substances ordered ","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/CVS\">CVS Health Corp.</a> and <a href=\"https://laohu8.com/S/WMT\">Walmart Inc.</a> will stop filling prescriptions for controlled substances ordered by clinicians working for Cerebral Inc. and Done Health, the broadest curbs yet by major pharmacies against the telehealth companies following scrutiny of their prescription practices.</p><p>A CVS spokesman confirmed the change, citing concerns with the two companies following a review it conducted. Cerebral had earlier disclosed the change to The Wall Street Journal. A Walmart spokeswoman said the retail giant is taking steps to no longer fill those prescriptions but didn&#39;t elaborate on why it made the decision.</p><p>&#34;Walmart is committed to patient safety and well-being,&#34; the spokeswoman said. &#34;We have an audit and compliance process in place that guides our decisions.&#34; Walmart, the largest retailer by revenue, operates some 5,000 U.S. pharmacy locations and last year bought a telehealth startup now called Walmart Health Virtual Care. That unit doesn&#39;t prescribe controlled substances, the spokeswoman said.</p><p>Cerebral called CVS&#39;s decision unfortunate, adding that it was &#34;doing everything possible to ensure these patients get access to medications that their healthcare providers have determined they need.&#34; Cerebral didn&#39;t immediately respond to a request for comment about Walmart&#39;s decision.</p><p>The moves by CVS and Walmart are the most sweeping actions taken by major pharmacies to limit certain prescriptions by the telehealth companies as they face scrutiny over how they have used medication to treat attention-deficit hyperactivity disorder. Federal prosecutors have begun an investigation into the issue, and subpoenaed Cerebral earlier this month. The company replaced its chief executive about a week after disclosing the subpoena.</p><p>Between them, Cerebral and Done treat tens of thousands of patients for ADHD, prescribing stimulants such as Adderall. Psychiatrists say stimulants can have significant benefits for people properly diagnosed with ADHD. But the drugs are classified as schedule 2 controlled substances by the federal government due to their potential for abuse, the same category as OxyContin and Vicodin.</p><p>Cerebral and Done grew quickly from the onset of the Covid-19 pandemic, attracting patients with social-media ads that offered an ADHD diagnosis and prescriptions to treat the condition. Previously, clinicians were prohibited from prescribing stimulants without an in-person visit. The U.S. relaxed those rules in March 2020 for all schedule 2 substances due to the coronavirus public-health emergency.</p><p>Fast growth for Cerebral and Done coincided with increasing demand for online health services and stimulants like Adderall. Prescriptions of the medication dispensed in the U.S. jumped to 41.4 million last year, up 10% from 2020, according to Iqvia Holdings Inc., a data and research-services provider for the pharmaceutical industry.</p><p>The Journal reported in March that current and former employees said they felt Cerebral and Done pressured clinicians to prescribe stimulants. Some of them said the companies&#39; initial 30-minute video evaluations often weren&#39;t sufficient to properly diagnose ADHD. Cerebral and Done said that they don&#39;t pressure clinicians to prescribe stimulants and that they are providing an essential service in the U.S., where demand for mental-health treatment far outstrips supply.</p><p>Cerebral said its clinicians can schedule an unlimited number of appointments. Done said systems and software help complete its initial consultations within 30 minutes.</p><p>Cerebral said this month that its medical group received a subpoena from the U.S. attorney&#39;s office for the Eastern District of New York as part of an investigation into possible violations of the Controlled Substances Act. The company said that it would cooperate with the investigation and that no regulatory or law-enforcement authority had accused it of violating any law.</p><p>CVS declined to elaborate on the concerns that prompted its change. &#34;We can&#39;t disclose specifics, other than it relates to their policies and practices with regard to controlled substances,&#34; the spokesman said in an email.</p><p>Before CVS&#39;s actions, some pharmacies had earlier blocked or delayed certain prescriptions from Cerebral and Done prescribers on a more limited basis over concerns that clinicians were writing too many stimulant prescriptions.</p><p>Walmart told the Journal in April that it had blocked some prescribers affiliated with Done. Individual locations of CVS and <a href=\"https://laohu8.com/S/WBA\">Walgreens Boots Alliance</a> Inc. had also blocked or delayed prescriptions from Done providers, and some Cerebral clinicians similarly had their prescriptions blocked or delayed for controlled substances, the Journal reported at the time.</p><p>Cerebral had said prescription delays occurred because of confusion around telehealth policies. Done declined to comment at the time.</p><p>Cerebral&#39;s preferred pharmacy, Truepill Inc., said this month that it would stop filling prescriptions for schedule 2 controlled substances such as Adderall. The online pharmacy company said it was taking the step out of &#34;an abundance of caution&#34; while it evaluated appropriate next steps. Cerebral said at the time that Truepill&#39;s action affected less than 2% of its total prescriptions.</p><p>Last week, Cerebral said it would stop prescribing almost all controlled substances, excluding those used to treat opioid-use disorder. It said the move would take effect for new patients May 20 but not until October for existing patients so they could transition to in-person care or taper off their medication.</p><p>Co-founder Kyle Robertson, then CEO, said in an internal email announcing the change that Cerebral had started prescribing controlled substances in 2020 to help patients needing medication who couldn&#39;t get in-person treatment during the pandemic -- and that it was halting most such prescriptions because of patients&#39; increased ability to return to in-person or hybrid treatment.</p><p>Soon after that announcement, Cerebral&#39;s board voted to oust Mr. Robertson. Directors lost confidence in his leadership because of what they felt was the company&#39;s aggressive strategy to diagnose and treat ADHD with stimulants, the Journal reported last week, citing people familiar with their thinking. Mr. Robertson said in a memo to the board that directors had encouraged Cerebral to prescribe Adderall -- and that his ousting was an attempt to make him a scapegoat for the startup&#39;s troubles.</p><p>CVS&#39;s decision means that patients relying on the pharmacy chain to fulfill prescriptions from Cerebral will have to find alternatives. The CVS spokesman said patients using Cerebral and Done for controlled-substance prescriptions &#34;will need to get them filled at another pharmacy.&#34; Cerebral said it is reaching out to affected patients to help with their transition to another source of prescribed medications. Done didn&#39;t respond to requests for comment.</p><p>In targeting all controlled substances from the telehealth startups, CVS&#39;s change will affect medication used to treat opioid addiction -- the <a href=\"https://laohu8.com/S/AONE.U\">one</a> type of medication that Cerebral has planned to continue prescribing and that has been a growth opportunity for the company. As part of its halt, CVS will no longer fill Cerebral&#39;s prescriptions for suboxone, a schedule 3 controlled substance used to treat such addictions.</p><p>Mr. Robertson had said in his internal email last week that Cerebral would continue prescribing opioid-treatment drugs because &#34;the size and needs of this vulnerable population are too great to discontinue care.&#34;</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Walmart, CVS Will Stop Filling Controlled-Substance Prescriptions for Cerebral</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWalmart, CVS Will Stop Filling Controlled-Substance Prescriptions for Cerebral\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-05-26 09:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/CVS\">CVS Health Corp.</a> and <a href=\"https://laohu8.com/S/WMT\">Walmart Inc.</a> will stop filling prescriptions for controlled substances ordered by clinicians working for Cerebral Inc. and Done Health, the broadest curbs yet by major pharmacies against the telehealth companies following scrutiny of their prescription practices.</p><p>A CVS spokesman confirmed the change, citing concerns with the two companies following a review it conducted. Cerebral had earlier disclosed the change to The Wall Street Journal. A Walmart spokeswoman said the retail giant is taking steps to no longer fill those prescriptions but didn&#39;t elaborate on why it made the decision.</p><p>&#34;Walmart is committed to patient safety and well-being,&#34; the spokeswoman said. &#34;We have an audit and compliance process in place that guides our decisions.&#34; Walmart, the largest retailer by revenue, operates some 5,000 U.S. pharmacy locations and last year bought a telehealth startup now called Walmart Health Virtual Care. That unit doesn&#39;t prescribe controlled substances, the spokeswoman said.</p><p>Cerebral called CVS&#39;s decision unfortunate, adding that it was &#34;doing everything possible to ensure these patients get access to medications that their healthcare providers have determined they need.&#34; Cerebral didn&#39;t immediately respond to a request for comment about Walmart&#39;s decision.</p><p>The moves by CVS and Walmart are the most sweeping actions taken by major pharmacies to limit certain prescriptions by the telehealth companies as they face scrutiny over how they have used medication to treat attention-deficit hyperactivity disorder. Federal prosecutors have begun an investigation into the issue, and subpoenaed Cerebral earlier this month. The company replaced its chief executive about a week after disclosing the subpoena.</p><p>Between them, Cerebral and Done treat tens of thousands of patients for ADHD, prescribing stimulants such as Adderall. Psychiatrists say stimulants can have significant benefits for people properly diagnosed with ADHD. But the drugs are classified as schedule 2 controlled substances by the federal government due to their potential for abuse, the same category as OxyContin and Vicodin.</p><p>Cerebral and Done grew quickly from the onset of the Covid-19 pandemic, attracting patients with social-media ads that offered an ADHD diagnosis and prescriptions to treat the condition. Previously, clinicians were prohibited from prescribing stimulants without an in-person visit. The U.S. relaxed those rules in March 2020 for all schedule 2 substances due to the coronavirus public-health emergency.</p><p>Fast growth for Cerebral and Done coincided with increasing demand for online health services and stimulants like Adderall. Prescriptions of the medication dispensed in the U.S. jumped to 41.4 million last year, up 10% from 2020, according to Iqvia Holdings Inc., a data and research-services provider for the pharmaceutical industry.</p><p>The Journal reported in March that current and former employees said they felt Cerebral and Done pressured clinicians to prescribe stimulants. Some of them said the companies&#39; initial 30-minute video evaluations often weren&#39;t sufficient to properly diagnose ADHD. Cerebral and Done said that they don&#39;t pressure clinicians to prescribe stimulants and that they are providing an essential service in the U.S., where demand for mental-health treatment far outstrips supply.</p><p>Cerebral said its clinicians can schedule an unlimited number of appointments. Done said systems and software help complete its initial consultations within 30 minutes.</p><p>Cerebral said this month that its medical group received a subpoena from the U.S. attorney&#39;s office for the Eastern District of New York as part of an investigation into possible violations of the Controlled Substances Act. The company said that it would cooperate with the investigation and that no regulatory or law-enforcement authority had accused it of violating any law.</p><p>CVS declined to elaborate on the concerns that prompted its change. &#34;We can&#39;t disclose specifics, other than it relates to their policies and practices with regard to controlled substances,&#34; the spokesman said in an email.</p><p>Before CVS&#39;s actions, some pharmacies had earlier blocked or delayed certain prescriptions from Cerebral and Done prescribers on a more limited basis over concerns that clinicians were writing too many stimulant prescriptions.</p><p>Walmart told the Journal in April that it had blocked some prescribers affiliated with Done. Individual locations of CVS and <a href=\"https://laohu8.com/S/WBA\">Walgreens Boots Alliance</a> Inc. had also blocked or delayed prescriptions from Done providers, and some Cerebral clinicians similarly had their prescriptions blocked or delayed for controlled substances, the Journal reported at the time.</p><p>Cerebral had said prescription delays occurred because of confusion around telehealth policies. Done declined to comment at the time.</p><p>Cerebral&#39;s preferred pharmacy, Truepill Inc., said this month that it would stop filling prescriptions for schedule 2 controlled substances such as Adderall. The online pharmacy company said it was taking the step out of &#34;an abundance of caution&#34; while it evaluated appropriate next steps. Cerebral said at the time that Truepill&#39;s action affected less than 2% of its total prescriptions.</p><p>Last week, Cerebral said it would stop prescribing almost all controlled substances, excluding those used to treat opioid-use disorder. It said the move would take effect for new patients May 20 but not until October for existing patients so they could transition to in-person care or taper off their medication.</p><p>Co-founder Kyle Robertson, then CEO, said in an internal email announcing the change that Cerebral had started prescribing controlled substances in 2020 to help patients needing medication who couldn&#39;t get in-person treatment during the pandemic -- and that it was halting most such prescriptions because of patients&#39; increased ability to return to in-person or hybrid treatment.</p><p>Soon after that announcement, Cerebral&#39;s board voted to oust Mr. Robertson. Directors lost confidence in his leadership because of what they felt was the company&#39;s aggressive strategy to diagnose and treat ADHD with stimulants, the Journal reported last week, citing people familiar with their thinking. Mr. Robertson said in a memo to the board that directors had encouraged Cerebral to prescribe Adderall -- and that his ousting was an attempt to make him a scapegoat for the startup&#39;s troubles.</p><p>CVS&#39;s decision means that patients relying on the pharmacy chain to fulfill prescriptions from Cerebral will have to find alternatives. The CVS spokesman said patients using Cerebral and Done for controlled-substance prescriptions &#34;will need to get them filled at another pharmacy.&#34; Cerebral said it is reaching out to affected patients to help with their transition to another source of prescribed medications. Done didn&#39;t respond to requests for comment.</p><p>In targeting all controlled substances from the telehealth startups, CVS&#39;s change will affect medication used to treat opioid addiction -- the <a href=\"https://laohu8.com/S/AONE.U\">one</a> type of medication that Cerebral has planned to continue prescribing and that has been a growth opportunity for the company. As part of its halt, CVS will no longer fill Cerebral&#39;s prescriptions for suboxone, a schedule 3 controlled substance used to treat such addictions.</p><p>Mr. Robertson had said in his internal email last week that Cerebral would continue prescribing opioid-treatment drugs because &#34;the size and needs of this vulnerable population are too great to discontinue care.&#34;</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4196":"保健护理服务","BK4534":"瑞士信贷持仓","BK4581":"高盛持仓","BK4155":"大卖场与超市","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4504":"桥水持仓","WMT":"沃尔玛","CVS":"西维斯健康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2238472135","content_text":"CVS Health Corp. and Walmart Inc. will stop filling prescriptions for controlled substances ordered by clinicians working for Cerebral Inc. and Done Health, the broadest curbs yet by major pharmacies against the telehealth companies following scrutiny of their prescription practices.A CVS spokesman confirmed the change, citing concerns with the two companies following a review it conducted. Cerebral had earlier disclosed the change to The Wall Street Journal. A Walmart spokeswoman said the retail giant is taking steps to no longer fill those prescriptions but didn't elaborate on why it made the decision.\"Walmart is committed to patient safety and well-being,\" the spokeswoman said. \"We have an audit and compliance process in place that guides our decisions.\" Walmart, the largest retailer by revenue, operates some 5,000 U.S. pharmacy locations and last year bought a telehealth startup now called Walmart Health Virtual Care. That unit doesn't prescribe controlled substances, the spokeswoman said.Cerebral called CVS's decision unfortunate, adding that it was \"doing everything possible to ensure these patients get access to medications that their healthcare providers have determined they need.\" Cerebral didn't immediately respond to a request for comment about Walmart's decision.The moves by CVS and Walmart are the most sweeping actions taken by major pharmacies to limit certain prescriptions by the telehealth companies as they face scrutiny over how they have used medication to treat attention-deficit hyperactivity disorder. Federal prosecutors have begun an investigation into the issue, and subpoenaed Cerebral earlier this month. The company replaced its chief executive about a week after disclosing the subpoena.Between them, Cerebral and Done treat tens of thousands of patients for ADHD, prescribing stimulants such as Adderall. Psychiatrists say stimulants can have significant benefits for people properly diagnosed with ADHD. But the drugs are classified as schedule 2 controlled substances by the federal government due to their potential for abuse, the same category as OxyContin and Vicodin.Cerebral and Done grew quickly from the onset of the Covid-19 pandemic, attracting patients with social-media ads that offered an ADHD diagnosis and prescriptions to treat the condition. Previously, clinicians were prohibited from prescribing stimulants without an in-person visit. The U.S. relaxed those rules in March 2020 for all schedule 2 substances due to the coronavirus public-health emergency.Fast growth for Cerebral and Done coincided with increasing demand for online health services and stimulants like Adderall. Prescriptions of the medication dispensed in the U.S. jumped to 41.4 million last year, up 10% from 2020, according to Iqvia Holdings Inc., a data and research-services provider for the pharmaceutical industry.The Journal reported in March that current and former employees said they felt Cerebral and Done pressured clinicians to prescribe stimulants. Some of them said the companies' initial 30-minute video evaluations often weren't sufficient to properly diagnose ADHD. Cerebral and Done said that they don't pressure clinicians to prescribe stimulants and that they are providing an essential service in the U.S., where demand for mental-health treatment far outstrips supply.Cerebral said its clinicians can schedule an unlimited number of appointments. Done said systems and software help complete its initial consultations within 30 minutes.Cerebral said this month that its medical group received a subpoena from the U.S. attorney's office for the Eastern District of New York as part of an investigation into possible violations of the Controlled Substances Act. The company said that it would cooperate with the investigation and that no regulatory or law-enforcement authority had accused it of violating any law.CVS declined to elaborate on the concerns that prompted its change. \"We can't disclose specifics, other than it relates to their policies and practices with regard to controlled substances,\" the spokesman said in an email.Before CVS's actions, some pharmacies had earlier blocked or delayed certain prescriptions from Cerebral and Done prescribers on a more limited basis over concerns that clinicians were writing too many stimulant prescriptions.Walmart told the Journal in April that it had blocked some prescribers affiliated with Done. Individual locations of CVS and Walgreens Boots Alliance Inc. had also blocked or delayed prescriptions from Done providers, and some Cerebral clinicians similarly had their prescriptions blocked or delayed for controlled substances, the Journal reported at the time.Cerebral had said prescription delays occurred because of confusion around telehealth policies. Done declined to comment at the time.Cerebral's preferred pharmacy, Truepill Inc., said this month that it would stop filling prescriptions for schedule 2 controlled substances such as Adderall. The online pharmacy company said it was taking the step out of \"an abundance of caution\" while it evaluated appropriate next steps. Cerebral said at the time that Truepill's action affected less than 2% of its total prescriptions.Last week, Cerebral said it would stop prescribing almost all controlled substances, excluding those used to treat opioid-use disorder. It said the move would take effect for new patients May 20 but not until October for existing patients so they could transition to in-person care or taper off their medication.Co-founder Kyle Robertson, then CEO, said in an internal email announcing the change that Cerebral had started prescribing controlled substances in 2020 to help patients needing medication who couldn't get in-person treatment during the pandemic -- and that it was halting most such prescriptions because of patients' increased ability to return to in-person or hybrid treatment.Soon after that announcement, Cerebral's board voted to oust Mr. Robertson. Directors lost confidence in his leadership because of what they felt was the company's aggressive strategy to diagnose and treat ADHD with stimulants, the Journal reported last week, citing people familiar with their thinking. Mr. Robertson said in a memo to the board that directors had encouraged Cerebral to prescribe Adderall -- and that his ousting was an attempt to make him a scapegoat for the startup's troubles.CVS's decision means that patients relying on the pharmacy chain to fulfill prescriptions from Cerebral will have to find alternatives. The CVS spokesman said patients using Cerebral and Done for controlled-substance prescriptions \"will need to get them filled at another pharmacy.\" Cerebral said it is reaching out to affected patients to help with their transition to another source of prescribed medications. Done didn't respond to requests for comment.In targeting all controlled substances from the telehealth startups, CVS's change will affect medication used to treat opioid addiction -- the one type of medication that Cerebral has planned to continue prescribing and that has been a growth opportunity for the company. As part of its halt, CVS will no longer fill Cerebral's prescriptions for suboxone, a schedule 3 controlled substance used to treat such addictions.Mr. Robertson had said in his internal email last week that Cerebral would continue prescribing opioid-treatment drugs because \"the size and needs of this vulnerable population are too great to discontinue care.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9022254177,"gmtCreate":1653535130499,"gmtModify":1676535300520,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Strong]&nbsp;","listText":"<a href=\"https://ttm.financial/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Strong]&nbsp;","text":"$NXP Semiconductors NV(NXPI)$[Strong]","images":[{"img":"https://community-static.tradeup.com/news/66634dbe42992479932b42059bf08e84","width":"750","height":"2009"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9022254177","isVote":1,"tweetType":1,"viewCount":135,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9022254923,"gmtCreate":1653535097962,"gmtModify":1676535300520,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/EDAP\">$Edap TMS SA(EDAP)$</a>[Strong]&nbsp;","listText":"<a href=\"https://ttm.financial/S/EDAP\">$Edap TMS SA(EDAP)$</a>[Strong]&nbsp;","text":"$Edap TMS SA(EDAP)$[Strong]","images":[{"img":"https://community-static.tradeup.com/news/c8bbe7e282470f0056f6064bf780ee8c","width":"750","height":"1869"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9022254923","isVote":1,"tweetType":1,"viewCount":86,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9023159308,"gmtCreate":1652884589504,"gmtModify":1676535181015,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/EDAP\">$Edap TMS SA(EDAP)$</a>[Strong]&nbsp;","listText":"<a href=\"https://ttm.financial/S/EDAP\">$Edap TMS SA(EDAP)$</a>[Strong]&nbsp;","text":"$Edap TMS SA(EDAP)$[Strong]","images":[{"img":"https://community-static.tradeup.com/news/f7b945107add93ff8d586dc591e4fbdb","width":"750","height":"1939"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9023159308","isVote":1,"tweetType":1,"viewCount":110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":832627909,"gmtCreate":1629624844701,"gmtModify":1676530081815,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>great&nbsp;","listText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>great&nbsp;","text":"$ASML Holding NV(ASML)$great","images":[{"img":"https://static.tigerbbs.com/2d460636c579ea254a9dca5d3b66a6e6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/832627909","isVote":1,"tweetType":1,"viewCount":226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":890521895,"gmtCreate":1628124677717,"gmtModify":1703501611140,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>??","listText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>??","text":"$ASML Holding NV(ASML)$??","images":[{"img":"https://static.tigerbbs.com/1f66ee6b16a6386239531a5e635b9292","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890521895","isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":897031724,"gmtCreate":1628862285368,"gmtModify":1676529878405,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>???","listText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>???","text":"$ASML Holding NV(ASML)$???","images":[{"img":"https://static.tigerbbs.com/d96898c82d9dc8ece7d58928d1e47622","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897031724","isVote":1,"tweetType":1,"viewCount":12,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":896029508,"gmtCreate":1628544651704,"gmtModify":1703507739452,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"FB up up up","listText":"FB up up up","text":"FB up up up","images":[{"img":"https://static.tigerbbs.com/495fdda275cbcff1194f62630eab3108","width":"1080","height":"4177"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/896029508","isVote":1,"tweetType":1,"viewCount":63,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":174384530,"gmtCreate":1627079420920,"gmtModify":1703483752687,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/174384530","repostId":"2153983997","repostType":4,"repost":{"id":"2153983997","pubTimestamp":1627045860,"share":"https://www.laohu8.com/m/news/2153983997?lang=&edition=full","pubTime":"2021-07-23 21:11","market":"us","language":"en","title":"3 Stocks to Buy Whether or Not a Market Crash Is Near","url":"https://stock-news.laohu8.com/highlight/detail?id=2153983997","media":"Motley Fool","summary":"Maybe the market is about to crash, and maybe it isn't. These stocks look like good picks either way.","content":"<p>Rising COVID-19 cases. Concerns about the highly contagious delta variant. The possibility of another housing bubble bursting. These are some of the reasons why worries are increasing among investors that a stock market crash could be on the way.</p>\n<p>One of the biggest stock market bears, Harry Dent Jr., who predicted the dot.com bubble collapsing, even thinks that a market meltdown is likely within the next three months. Is all of the pessimism warranted? Maybe, maybe not.</p>\n<p>If you're leery about what's around the corner, here are three stocks to buy if a market crash is coming soon. And the great news about these stocks is that they're solid picks even if it doesn't happen.</p>\n<p><img src=\"https://static.tigerbbs.com/3105d12ec8b203883b5e91a709172e8b\" tg-width=\"700\" tg-height=\"514\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>BioNTech</h3>\n<p>I personally don't think a stock market crash is just around the corner. If <a href=\"https://laohu8.com/S/AONE.U\">one</a> is, though, I suspect the cause will be the combination of the COVID-19 pandemic and sky-high market valuations. Assuming I'm right,&nbsp;<b>BioNTech</b> (NASDAQ:BNTX) should soar if the market crashes.</p>\n<p>A massive market sell-off due to COVID-19 worries would almost certainly light a fire beneath the stocks of the leading vaccine makers. My view is that BioNTech would be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners in the group.</p>\n<p>BioNTech and its partner <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> (NYSE:PFE) are already moving forward with plans to test a vaccine that specifically targets the delta variant. That gives the companies a head start. BioNTech is by far the smallest of the companies with COVID-19 vaccines already on the market, which makes its shares more likely to jump higher on a positive catalyst. It's also easily the cheapest of these vaccine stocks, based on forward earnings multiples.</p>\n<p>What if there isn't an imminent market crash? BioNTech is still set to rake in billions of dollars with sales of its COVID-19 vaccine. The company will almost certainly use its growing cash stockpile to invest in expanding its pipeline. I think that BioNTech will be a winner over the long term, regardless of what happens over the short term.</p>\n<h3><a href=\"https://laohu8.com/S/DG\">Dollar General</a></h3>\n<p>I've maintained for a long time that&nbsp;<b>Dollar <a href=\"https://laohu8.com/S/BGC\">General</a></b> (NYSE:DG) is one of the best stocks to own during a market downturn. That view seemed to be confirmed during the big market meltdown last year.</p>\n<p><img src=\"https://static.tigerbbs.com/b0e75aa27d2d22b4296c80687da5be97\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\"></p>\n<p>DG data by YCharts.</p>\n<p>Shares of Dollar General fell at first, but not nearly as much as most stocks did. Dollar General stock also rebounded much more quickly and trounced the overall market's return throughout the rest of the year.</p>\n<p>During uncertain times, consumers tighten their purse strings. That makes discount retailers such as Dollar General more attractive than ever.</p>\n<p>Even when the overall market performs well, though, Dollar General should still be able to grow. As a case in point, the company's shares delivered more than double the gain that the <b>S&amp;P 500</b> index did in the five years leading up to 2020 when the market was roaring.</p>\n<p>I think that Dollar General will be able to continue to beat the market. It's moving forward with an aggressive expansion strategy. The company is also undertaking a major initiative to \"establish itself as a health destination.\" While Dollar General didn't provide many details on exactly what its plans are, moving more into healthcare sounds like a smart move to me.</p>\n<h3>Viatris</h3>\n<p>There are at least two reasons why a given stock might hold up well during a big market sell-off. One is that its underlying business isn't impacted much by the reason behind the broader plunge. Another is that the stock is so cheap that investors scoop up shares if it falls much below its existing price. My take is that&nbsp;<b>Viatris</b> (NASDAQ:VTRS) qualifies on both of these criteria.</p>\n<p>Viatris specializes in biosimilars and generic drugs. Patients need these drugs, regardless of what the stock market does. The drugs are also less expensive than branded prescription drugs.</p>\n<p>The stock is irrefutably dirt cheap. Viatris' shares trade at a little over four times expected earnings. It's unlikely that the stock is going to move much lower because it would simply be too much of a steal for investors to ignore.</p>\n<p>Granted, Viatris probably won't keep up with the overall stock market's performance if the current uptrend continues. However, the company's dividend is attractive. And over the next several years, Viatris should achieve synergies resulting from the merger of Pfizer's Upjohn unit and Mylan, as well as launch new products that should drive growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Buy Whether or Not a Market Crash Is Near</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Buy Whether or Not a Market Crash Is Near\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/3-stocks-to-buy-whether-or-not-a-market-crash-is-n/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rising COVID-19 cases. Concerns about the highly contagious delta variant. The possibility of another housing bubble bursting. These are some of the reasons why worries are increasing among investors ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/3-stocks-to-buy-whether-or-not-a-market-crash-is-n/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","DG":"美国达乐公司","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/3-stocks-to-buy-whether-or-not-a-market-crash-is-n/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153983997","content_text":"Rising COVID-19 cases. Concerns about the highly contagious delta variant. The possibility of another housing bubble bursting. These are some of the reasons why worries are increasing among investors that a stock market crash could be on the way.\nOne of the biggest stock market bears, Harry Dent Jr., who predicted the dot.com bubble collapsing, even thinks that a market meltdown is likely within the next three months. Is all of the pessimism warranted? Maybe, maybe not.\nIf you're leery about what's around the corner, here are three stocks to buy if a market crash is coming soon. And the great news about these stocks is that they're solid picks even if it doesn't happen.\n\nImage source: Getty Images.\nBioNTech\nI personally don't think a stock market crash is just around the corner. If one is, though, I suspect the cause will be the combination of the COVID-19 pandemic and sky-high market valuations. Assuming I'm right, BioNTech (NASDAQ:BNTX) should soar if the market crashes.\nA massive market sell-off due to COVID-19 worries would almost certainly light a fire beneath the stocks of the leading vaccine makers. My view is that BioNTech would be one of the biggest winners in the group.\nBioNTech and its partner Pfizer (NYSE:PFE) are already moving forward with plans to test a vaccine that specifically targets the delta variant. That gives the companies a head start. BioNTech is by far the smallest of the companies with COVID-19 vaccines already on the market, which makes its shares more likely to jump higher on a positive catalyst. It's also easily the cheapest of these vaccine stocks, based on forward earnings multiples.\nWhat if there isn't an imminent market crash? BioNTech is still set to rake in billions of dollars with sales of its COVID-19 vaccine. The company will almost certainly use its growing cash stockpile to invest in expanding its pipeline. I think that BioNTech will be a winner over the long term, regardless of what happens over the short term.\nDollar General\nI've maintained for a long time that Dollar General (NYSE:DG) is one of the best stocks to own during a market downturn. That view seemed to be confirmed during the big market meltdown last year.\n\nDG data by YCharts.\nShares of Dollar General fell at first, but not nearly as much as most stocks did. Dollar General stock also rebounded much more quickly and trounced the overall market's return throughout the rest of the year.\nDuring uncertain times, consumers tighten their purse strings. That makes discount retailers such as Dollar General more attractive than ever.\nEven when the overall market performs well, though, Dollar General should still be able to grow. As a case in point, the company's shares delivered more than double the gain that the S&P 500 index did in the five years leading up to 2020 when the market was roaring.\nI think that Dollar General will be able to continue to beat the market. It's moving forward with an aggressive expansion strategy. The company is also undertaking a major initiative to \"establish itself as a health destination.\" While Dollar General didn't provide many details on exactly what its plans are, moving more into healthcare sounds like a smart move to me.\nViatris\nThere are at least two reasons why a given stock might hold up well during a big market sell-off. One is that its underlying business isn't impacted much by the reason behind the broader plunge. Another is that the stock is so cheap that investors scoop up shares if it falls much below its existing price. My take is that Viatris (NASDAQ:VTRS) qualifies on both of these criteria.\nViatris specializes in biosimilars and generic drugs. Patients need these drugs, regardless of what the stock market does. The drugs are also less expensive than branded prescription drugs.\nThe stock is irrefutably dirt cheap. Viatris' shares trade at a little over four times expected earnings. It's unlikely that the stock is going to move much lower because it would simply be too much of a steal for investors to ignore.\nGranted, Viatris probably won't keep up with the overall stock market's performance if the current uptrend continues. However, the company's dividend is attractive. And over the next several years, Viatris should achieve synergies resulting from the merger of Pfizer's Upjohn unit and Mylan, as well as launch new products that should drive growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174385263,"gmtCreate":1627079299452,"gmtModify":1703483750885,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>???","listText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>???","text":"$ASML Holding NV(ASML)$???","images":[{"img":"https://static.tigerbbs.com/7c15a955f47379cdf8a4ddeff3776473","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/174385263","isVote":1,"tweetType":1,"viewCount":204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9057171558,"gmtCreate":1655483311474,"gmtModify":1676535649074,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>🤞🏻","listText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>🤞🏻","text":"$ON Semiconductor(ON)$🤞🏻","images":[{"img":"https://community-static.tradeup.com/news/1c00c211013e3be3ffc0f0a3fc3b3191","width":"1080","height":"4065"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9057171558","isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9055002161,"gmtCreate":1655216221253,"gmtModify":1676535586014,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/IFNNY\">$Infineon Technologies AG(IFNNY)$</a>[Strong]&nbsp;","listText":"<a href=\"https://ttm.financial/S/IFNNY\">$Infineon Technologies AG(IFNNY)$</a>[Strong]&nbsp;","text":"$Infineon Technologies AG(IFNNY)$[Strong]","images":[{"img":"https://community-static.tradeup.com/news/20347add9528c52df4684ffaa759062c","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9055002161","isVote":1,"tweetType":1,"viewCount":109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9066959484,"gmtCreate":1651842730548,"gmtModify":1676534981845,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[Speechless]&nbsp;","listText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[Speechless]&nbsp;","text":"$ON Semiconductor(ON)$[Speechless]","images":[{"img":"https://community-static.tradeup.com/news/ad7c0f06dde5233392c0455fc8b2198f","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066959484","isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9068691500,"gmtCreate":1651759202000,"gmtModify":1676534963725,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Miser]&nbsp;","listText":"<a href=\"https://ttm.financial/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Miser]&nbsp;","text":"$NXP Semiconductors NV(NXPI)$[Miser]","images":[{"img":"https://community-static.tradeup.com/news/ae5b913ab38ce52dab2c91cfc4460137","width":"750","height":"1879"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068691500","isVote":1,"tweetType":1,"viewCount":111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9085567077,"gmtCreate":1650729477233,"gmtModify":1676534783660,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[What]&nbsp;","listText":"<a href=\"https://ttm.financial/S/ON\">$ON Semiconductor(ON)$</a>[What]&nbsp;","text":"$ON Semiconductor(ON)$[What]","images":[{"img":"https://community-static.tradeup.com/news/aa5afa16cfc6af4c6ba2e1a25e33c062","width":"750","height":"2392"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9085567077","isVote":1,"tweetType":1,"viewCount":19,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9088928435,"gmtCreate":1650300106033,"gmtModify":1676534690830,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Sad]&nbsp;","listText":"<a href=\"https://ttm.financial/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Sad]&nbsp;","text":"$NXP Semiconductors NV(NXPI)$[Sad]","images":[{"img":"https://community-static.tradeup.com/news/be11326abb588db419ffcb7990dcc149","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088928435","isVote":1,"tweetType":1,"viewCount":108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9080747520,"gmtCreate":1649924491492,"gmtModify":1676534608322,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSM\">$Taiwan Semiconductor Manufacturing(TSM)$</a>👍🏻","listText":"<a href=\"https://ttm.financial/S/TSM\">$Taiwan Semiconductor Manufacturing(TSM)$</a>👍🏻","text":"$Taiwan Semiconductor Manufacturing(TSM)$👍🏻","images":[{"img":"https://community-static.tradeup.com/news/9f57b97dd408f9b018b463dab927fb34","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9080747520","isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9015537471,"gmtCreate":1649508389792,"gmtModify":1676534523168,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSM\">$Taiwan Semiconductor Manufacturing(TSM)$</a>[Cry]&nbsp;[Cry]&nbsp;","listText":"<a href=\"https://ttm.financial/S/TSM\">$Taiwan Semiconductor Manufacturing(TSM)$</a>[Cry]&nbsp;[Cry]&nbsp;","text":"$Taiwan Semiconductor Manufacturing(TSM)$[Cry] [Cry]","images":[{"img":"https://community-static.tradeup.com/news/04024d990d9d6487d73eaad3b143c8c3","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9015537471","isVote":1,"tweetType":1,"viewCount":83,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":888108033,"gmtCreate":1631449622622,"gmtModify":1676530549843,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$NVIDIA Corp(NVDA)$</a>moving upside?&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVDA\">$NVIDIA Corp(NVDA)$</a>moving upside?&nbsp;","text":"$NVIDIA Corp(NVDA)$moving upside?","images":[{"img":"https://static.tigerbbs.com/fead05df07b99a381e7363bfc01796a6","width":"1080","height":"4224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888108033","isVote":1,"tweetType":1,"viewCount":15,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":832054450,"gmtCreate":1629548512470,"gmtModify":1676530069104,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>???","listText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>???","text":"$ASML Holding NV(ASML)$???","images":[{"img":"https://static.tigerbbs.com/93f8fbcfda803e18b27b0fb80417112f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/832054450","isVote":1,"tweetType":1,"viewCount":86,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":807576154,"gmtCreate":1628046659678,"gmtModify":1703500219217,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Fantastic&nbsp;","listText":"Fantastic&nbsp;","text":"Fantastic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807576154","repostId":"1123853854","repostType":4,"repost":{"id":"1123853854","pubTimestamp":1628045254,"share":"https://www.laohu8.com/m/news/1123853854?lang=&edition=full","pubTime":"2021-08-04 10:47","market":"us","language":"en","title":"ASML: Strong Momentum Should Lead To Higher Revenue Expectations At Upcoming Investor Day","url":"https://stock-news.laohu8.com/highlight/detail?id=1123853854","media":"seekingalpha","summary":"Summary\n\nASML recently reported Q2 2021 earnings that were quite good, while the order intake was im","content":"<p><b>Summary</b></p>\n<ul>\n <li>ASML recently reported Q2 2021 earnings that were quite good, while the order intake was impressive, and also announced a new share buyback program.</li>\n <li>My medium-term expectations for EUV sales were confirmed by the company, which means that ASML will certainly raise its 2025 revenue estimates at its upcoming investor day.</li>\n <li>The stock has reached consecutive new all-time highs in recent months, but there is still upside in the short term.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5cbbfa8ed4239d6e8d29d42367fc89fa\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"><span>Michael Vi/iStock Editorial via Getty Images</span></p>\n<p><b>ASMLNV</b>(ASML) continues to be one of the best semiconductor stocks for long-term investors and the upcoming investor day can be an important catalyst for a higher share price.</p>\n<p>I have been bullish on ASML since my&nbsp;first article&nbsp;was published on the company last March, even though I’ve taken some profits recently because this stock was my largest holding and I wanted to diversify my portfolio a little bit.</p>\n<p>Since then, the company has reported earnings related to Q2 2021, that continued to show a great operating performance, and my growth expectations were upgraded due to bullish comments from the company.</p>\n<p><b>Recent Earnings</b></p>\n<p>In Q2 2021, ASML reported strong revenue and earnings growth, showing that its operating momentum continues to be quite strong. Its revenues increased by 21% YoY to €4 billion, which was slightly below estimates, while its net income was around €1 billion and EPS was €2.52 (+41% YoY), ahead of sell-side expectations.</p>\n<p>During the quarter, ASML’s net systems sales amounted to €2.9 billion, while its Installed Base Management sales were €1.1 billion. This revenue from Installed Based Management was above the company’s guidance of around €900 million and is justified by the current situation in the semiconductor industry (the chip shortage) that is pushing customers to software upgrades to improve productivity of the systems.</p>\n<p>In this last quarter, ASML has recognized revenue fornineEUV units, compared tosevenunits in the previous quarter, even though it has delivered 10 units to customers and will recognize revenue for the remaining unit in the next quarter. EUV revenue represented 45% of its system sales in the quarter, compared to 36% in the previous quarter, and shows that EUV should be its major growth source in the next few quarters.</p>\n<p>At this pace, ASML should increase the number of EUV units delivered in 2020 compared to the previous year (it delivered 31 EUV units), but it may miss my expectation of about 38 units delivered this year if deliveries do not ramp a little bit up in the next two quarters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5a48a69a3ba61e82df997470af977ae5\" tg-width=\"1042\" tg-height=\"252\" width=\"100%\" height=\"auto\"><span>Source: ASML.</span></p>\n<p>ASML’s gross margin of 50.9% was above its prior guidance, mainly due to software upgrades that weren’t expected. Its gross margin outlook for the full year is between 51-52%, compared to 48.6% reported in 2020, another support for earnings growth in coming quarters.</p>\n<p>Regarding its net bookings, they were close to €8.3 billion, of which €4.9 billion is related to EUV systems, which is a reflection of the strong demand that currently exists in the semiconductor industry. This represents a great increase in bookings compared to the previous quarter (€4.7 billion in Q1), which is not totally surprising considering the recent announcements by its major customers&nbsp;<b>TSMC</b>(TSM) and&nbsp;<b>Intel</b>(INTC) of new factories and increased capex plans for the next couple of years, of which lithography machines are critical elements.</p>\n<p>Beyond that, while the majority of orders for EUV units come from Logic customers, this quarter ASML had the greatest order intake from Memory customers, most likely from&nbsp;<b>Micron Technology</b>(MU) and&nbsp;<b>SK Hynix</b>(OTC:HXSCF), which is important to diversify its customer base that still is relatively concentrated regarding EUV units. Moreover, investors should also be aware that ASML is not selling EUV units in China, which could represent another growth source in the future if, eventually, the U.S.-China political relationships improve, even though I think that is unlikely at this stage.</p>\n<p>Going forward, the company raised its 2021 guidance and now expects net revenue growth of about 35% (previous expectations were for 30% annual revenue growth) and a gross margin between 51-52%. ASML has also guided for EUV revenue growth of about 35% YoY, which corresponds to some 39-40 units, thus the company is expecting to deliver a higher number of units in the second half of the year than in the previous six months, justified by its push to improve its manufacturing and supply chain capabilities.</p>\n<p>As&nbsp;I’ve discussed in a previous article, ASML was somewhat constrained to grow its EUV production and has made some efforts to increase production in the coming years. This was confirmed in the earnings call, with the company saying that it expects to deliver some 55 units in 2022, growing to over 60 units in 2023.</p>\n<p>I’ve forecasted in that previous analysis that ASML would grow its EUV sales by aroundfiveunits per year after 2022 and reach unit sales of around 70 units by 2025. This now seems to be a conservative estimate and ASML may easily beat my expectations of 70 units and around €11 billion in revenue from EUV by 2025, as demand for its systems is clearly very strong right now.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed697ade2047cb8381d563726e9a0864\" tg-width=\"600\" tg-height=\"396\" width=\"100%\" height=\"auto\"><span>Source: ASML and author’s calculations.</span></p>\n<p><b>Capital Returns &amp; Investor Day</b></p>\n<p>Beyond strong growth and profitability, another positive factor for a higher share price has been its capital return policy, given that ASML has a very good history both through dividends and share buybacks.</p>\n<p>This trend is not expected to change much over the long term and was reinforced recently. Indeed, as&nbsp;I’ve predicted in a previous article, the company increased its share buyback program to €9 billion, to be completed by the end of 2023, substituting immediately the previous program.</p>\n<p>This is a strong increase from its previous share buyback program of €6 billion that was to be completed this year (ASML completed €5.2 billion of this program), showing that ASML has a solid financial position that enables it to invest in the future of its business through R&amp;D and capex, but also return significant amounts of capital to shareholders.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/84129202a0103e8396a273c5740e57a1\" tg-width=\"500\" tg-height=\"223\" width=\"100%\" height=\"auto\"><span>Source: ASML.</span></p>\n<p>ASML is delivering impressive results and returning even more capital to shareholders, leading its stock to reach consecutive new all-time highs during the past few months. Despite this, there is still upside and this may become more evident in its upcoming investor day, where the company will update investors about its future scenarios regarding revenues and earnings.</p>\n<p>Indeed, ASML has scheduled an investor day on 29 September 2021, where it will certainly raise its medium-term targets compared to the targets set in 2018. Its current revenue target is for a range of €15-24 billion in annual revenues by 2025, which is clearly outdated, considering that ASML should reach revenues of about €19 billion this year.</p>\n<p>As I’ve said in previous articles, I expect ASML to increase its revenue target to a medium-level of around €30 billion or higher by 2025, a much higher level than current sell-side consensus' expectation in 2025 (€26.1 billion). Therefore, this investor day could be another catalyst for a higher share price in the short term, as sell-side estimates will most likely increase following this event. This could be an important driver for a higher share price in the next 3-6 months.</p>\n<p><b>Conclusion</b></p>\n<p>ASML has reported another good quarter with the strong order intake being the most impressive factor in my opinion. This is clearly a very bullish factor for ASML’s business in the next few years and a good support for higher revenue expectations in the medium term. I expect ASML to increase its revenue range at its upcoming investor day, which may be a positive catalyst for its share price in the coming months, and therefore remain bullish on ASML.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASML: Strong Momentum Should Lead To Higher Revenue Expectations At Upcoming Investor Day</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASML: Strong Momentum Should Lead To Higher Revenue Expectations At Upcoming Investor Day\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 10:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4444504-asml-strong-momentum-should-lead-to-higher-revenue-expectations-at-upcoming-investor-day><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nASML recently reported Q2 2021 earnings that were quite good, while the order intake was impressive, and also announced a new share buyback program.\nMy medium-term expectations for EUV sales ...</p>\n\n<a href=\"https://seekingalpha.com/article/4444504-asml-strong-momentum-should-lead-to-higher-revenue-expectations-at-upcoming-investor-day\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ASML":"阿斯麦"},"source_url":"https://seekingalpha.com/article/4444504-asml-strong-momentum-should-lead-to-higher-revenue-expectations-at-upcoming-investor-day","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123853854","content_text":"Summary\n\nASML recently reported Q2 2021 earnings that were quite good, while the order intake was impressive, and also announced a new share buyback program.\nMy medium-term expectations for EUV sales were confirmed by the company, which means that ASML will certainly raise its 2025 revenue estimates at its upcoming investor day.\nThe stock has reached consecutive new all-time highs in recent months, but there is still upside in the short term.\n\nMichael Vi/iStock Editorial via Getty Images\nASMLNV(ASML) continues to be one of the best semiconductor stocks for long-term investors and the upcoming investor day can be an important catalyst for a higher share price.\nI have been bullish on ASML since my first article was published on the company last March, even though I’ve taken some profits recently because this stock was my largest holding and I wanted to diversify my portfolio a little bit.\nSince then, the company has reported earnings related to Q2 2021, that continued to show a great operating performance, and my growth expectations were upgraded due to bullish comments from the company.\nRecent Earnings\nIn Q2 2021, ASML reported strong revenue and earnings growth, showing that its operating momentum continues to be quite strong. Its revenues increased by 21% YoY to €4 billion, which was slightly below estimates, while its net income was around €1 billion and EPS was €2.52 (+41% YoY), ahead of sell-side expectations.\nDuring the quarter, ASML’s net systems sales amounted to €2.9 billion, while its Installed Base Management sales were €1.1 billion. This revenue from Installed Based Management was above the company’s guidance of around €900 million and is justified by the current situation in the semiconductor industry (the chip shortage) that is pushing customers to software upgrades to improve productivity of the systems.\nIn this last quarter, ASML has recognized revenue fornineEUV units, compared tosevenunits in the previous quarter, even though it has delivered 10 units to customers and will recognize revenue for the remaining unit in the next quarter. EUV revenue represented 45% of its system sales in the quarter, compared to 36% in the previous quarter, and shows that EUV should be its major growth source in the next few quarters.\nAt this pace, ASML should increase the number of EUV units delivered in 2020 compared to the previous year (it delivered 31 EUV units), but it may miss my expectation of about 38 units delivered this year if deliveries do not ramp a little bit up in the next two quarters.\nSource: ASML.\nASML’s gross margin of 50.9% was above its prior guidance, mainly due to software upgrades that weren’t expected. Its gross margin outlook for the full year is between 51-52%, compared to 48.6% reported in 2020, another support for earnings growth in coming quarters.\nRegarding its net bookings, they were close to €8.3 billion, of which €4.9 billion is related to EUV systems, which is a reflection of the strong demand that currently exists in the semiconductor industry. This represents a great increase in bookings compared to the previous quarter (€4.7 billion in Q1), which is not totally surprising considering the recent announcements by its major customers TSMC(TSM) and Intel(INTC) of new factories and increased capex plans for the next couple of years, of which lithography machines are critical elements.\nBeyond that, while the majority of orders for EUV units come from Logic customers, this quarter ASML had the greatest order intake from Memory customers, most likely from Micron Technology(MU) and SK Hynix(OTC:HXSCF), which is important to diversify its customer base that still is relatively concentrated regarding EUV units. Moreover, investors should also be aware that ASML is not selling EUV units in China, which could represent another growth source in the future if, eventually, the U.S.-China political relationships improve, even though I think that is unlikely at this stage.\nGoing forward, the company raised its 2021 guidance and now expects net revenue growth of about 35% (previous expectations were for 30% annual revenue growth) and a gross margin between 51-52%. ASML has also guided for EUV revenue growth of about 35% YoY, which corresponds to some 39-40 units, thus the company is expecting to deliver a higher number of units in the second half of the year than in the previous six months, justified by its push to improve its manufacturing and supply chain capabilities.\nAs I’ve discussed in a previous article, ASML was somewhat constrained to grow its EUV production and has made some efforts to increase production in the coming years. This was confirmed in the earnings call, with the company saying that it expects to deliver some 55 units in 2022, growing to over 60 units in 2023.\nI’ve forecasted in that previous analysis that ASML would grow its EUV sales by aroundfiveunits per year after 2022 and reach unit sales of around 70 units by 2025. This now seems to be a conservative estimate and ASML may easily beat my expectations of 70 units and around €11 billion in revenue from EUV by 2025, as demand for its systems is clearly very strong right now.\nSource: ASML and author’s calculations.\nCapital Returns & Investor Day\nBeyond strong growth and profitability, another positive factor for a higher share price has been its capital return policy, given that ASML has a very good history both through dividends and share buybacks.\nThis trend is not expected to change much over the long term and was reinforced recently. Indeed, as I’ve predicted in a previous article, the company increased its share buyback program to €9 billion, to be completed by the end of 2023, substituting immediately the previous program.\nThis is a strong increase from its previous share buyback program of €6 billion that was to be completed this year (ASML completed €5.2 billion of this program), showing that ASML has a solid financial position that enables it to invest in the future of its business through R&D and capex, but also return significant amounts of capital to shareholders.\nSource: ASML.\nASML is delivering impressive results and returning even more capital to shareholders, leading its stock to reach consecutive new all-time highs during the past few months. Despite this, there is still upside and this may become more evident in its upcoming investor day, where the company will update investors about its future scenarios regarding revenues and earnings.\nIndeed, ASML has scheduled an investor day on 29 September 2021, where it will certainly raise its medium-term targets compared to the targets set in 2018. Its current revenue target is for a range of €15-24 billion in annual revenues by 2025, which is clearly outdated, considering that ASML should reach revenues of about €19 billion this year.\nAs I’ve said in previous articles, I expect ASML to increase its revenue target to a medium-level of around €30 billion or higher by 2025, a much higher level than current sell-side consensus' expectation in 2025 (€26.1 billion). Therefore, this investor day could be another catalyst for a higher share price in the short term, as sell-side estimates will most likely increase following this event. This could be an important driver for a higher share price in the next 3-6 months.\nConclusion\nASML has reported another good quarter with the strong order intake being the most impressive factor in my opinion. This is clearly a very bullish factor for ASML’s business in the next few years and a good support for higher revenue expectations in the medium term. I expect ASML to increase its revenue range at its upcoming investor day, which may be a positive catalyst for its share price in the coming months, and therefore remain bullish on ASML.","news_type":1},"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174363402,"gmtCreate":1627079856206,"gmtModify":1703483758022,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/174363402","repostId":"1183078855","repostType":4,"repost":{"id":"1183078855","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627047447,"share":"https://www.laohu8.com/m/news/1183078855?lang=&edition=full","pubTime":"2021-07-23 21:37","market":"other","language":"en","title":"Facebook rose over 2%, reaching record high","url":"https://stock-news.laohu8.com/highlight/detail?id=1183078855","media":"Tiger Newspress","summary":"(July 23) Facebook rose over 2%, reaching record high.","content":"<p>(July 23)&nbsp;<a href=\"https://laohu8.com/S/FB\">Facebook</a> rose over 2%, reaching record high.</p>\n<p><img src=\"https://static.tigerbbs.com/414e2c0bbd13f604e8a3aa78e542f33a\" tg-width=\"903\" tg-height=\"542\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook rose over 2%, reaching record high</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook rose over 2%, reaching record high\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-23 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(July 23)&nbsp;<a href=\"https://laohu8.com/S/FB\">Facebook</a> rose over 2%, reaching record high.</p>\n<p><img src=\"https://static.tigerbbs.com/414e2c0bbd13f604e8a3aa78e542f33a\" tg-width=\"903\" tg-height=\"542\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183078855","content_text":"(July 23) Facebook rose over 2%, reaching record high.","news_type":1},"isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176156548,"gmtCreate":1626873875384,"gmtModify":1703479662342,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176156548","repostId":"2153610463","repostType":4,"repost":{"id":"2153610463","pubTimestamp":1626867600,"share":"https://www.laohu8.com/m/news/2153610463?lang=&edition=full","pubTime":"2021-07-21 19:40","market":"us","language":"en","title":"4 Dow Stocks With 48% to 58% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2153610463","media":"Motley Fool","summary":"Are these Dow components the big-time bargains analysts make them out to be?","content":"<p>For the past 125 years, arguably no stock index has been more widely followed than the <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI). The Dow Jones, which is comprised of 30 profitable, time-tested, multinational businesses, has become a barometer to gauge the health of the U.S. stock market.</p><p>It's also home to some serious value, at least according to a handful of Wall Street analysts and investment banks. Wall Street's high-water <a href=\"https://laohu8.com/S/AONE.U\">one</a>-year price target for each of the following four Dow stocks implies upside ranging from 48% to as much as 58%.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F634050%2Fnyse-wall-street-trading-new-york-financial-stock-market-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Intel: Implied upside of 55%</h3><p>To begin with, at least one Wall Street analyst foresees some significant upside in semiconductor giant <b>Intel</b> (NASDAQ:INTC). According to Robert W. Baird analyst Tristan Gerra, Intel could hit $85 a share, representing upside of 55% over the next year.</p><p>Among Gerra's chief arguments is that Intel will likely make a big acquisition to shore up its Foundry Services operations. It just so happens that <i>The Wall Street Journal</i> reported last week that Intel is tinkering with the idea of a $30 billion deal to acquire GlobalFoundries, a specialty chip-production company that <b>Advanced Micro Devices</b>&nbsp;spun off back in 2008. Going the acquisition route would emphasize Intel's renewed commitment to keep chip production under its own control, rather than outsource it. Depending on geopolitical or supply and demand concerns, that could become a major competitive edge for Intel.</p><p>Even though personal-computing chip demand tends to ebb and flow, the future for Intel will likely hinge on data centers. Despite a double-digit percentage decline in data center revenue in the first quarter, demand for storage, processing, and software solutions are only going to increase over the long run as businesses make the shift online and into the cloud.&nbsp; Intel's road will undoubtedly be bumpy as it spends big bucks on 7nm chip innovation, but it should prove well worth it.</p><p>An $85 price target may well make sense for Intel, but likely not over the next year.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F634050%2Fpharmacist-dispensing-drugs-patient-cost-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Walgreen Boots Alliance: Implied upside of 48%</h3><p>Healthcare stocks are also expected to get in on the action. Pharmacy chain <b><a href=\"https://laohu8.com/S/WBA\">Walgreens Boots Alliance</a></b> (NASDAQ:WBA) has a high-end price target of $68 from analysts at Robert W. Baird. This portends up to 48% upside over the next 12 months.</p><p>The bullishness surrounding Walgreens likely has to do with the company's ongoing multipoint turnaround plan. By fiscal 2022, Walgreens should be realizing more than $2 billion in annual cost savings, yet at the same time will benefit from hefty investments in digitization. Although online sales only comprise a small portion of total sales, direct-to-consumer is an area of considerable growth opportunity for the generally slow-growing pharmacy chain.</p><p>Perhaps even more exciting is the partnership between Walgreens Boots Alliance and VillageMD. This duo plans to open as many as 700 full-service clinics (co-located in Walgreens' stores) in more than 30 markets throughout the United States by mid-decade.&nbsp; Whereas most in-store clinics cater to vaccines or a sniffle, doctor-led full-service practices inside Walgreens have the potential to facilitate repeat business and drive patients right to Walgreens' high-margin pharmacy.</p><p>As a shareholder, I'm enthusiastic about Walgreens' future. But I suspect it'll take longer than 12 months to reach $68.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F634050%2Fchemicals-manufacturing-plant-workers-steel-storage-tanks-tablet-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Dow Inc.: Implied upside of 58%</h3><p>When it comes to Dow stocks with supercharged return potential, chemicals company <b>Dow Inc.</b> (NYSE:DOW) takes the cake. If the Street-high price target of $95 were to come to fruition, Dow would return 58% for its shareholders over the coming year.</p><p>The biggest growth driver for Dow is going to be a continued U.S. and global recovery (Dow has a manufacturing presence in 31 countries). If economic activity continues to pick up, not only will the company recognize strong demand for its packaging, specialty plastics, performance materials, and coatings, but this demand will actually improve pricing power for Dow's material solutions. The first quarter saw demand and pricing power improve across all operating segments.</p><p>Beyond just growing demand, Dow is taking other actions to improve its bottom line. The company has invested aggressively in digitization, while at the same time restructuring its operations to eventually reduce costs by approximately $300 million on an annual basis. Perhaps most important, capacity expansion for its material solutions will allow Dow to meet increased demand as the U.S. and global economy heat up.</p><p>The bottom line is that Dow is a solid cyclical operating model that'll deliver incremental profit improvements in the years that lie ahead. But as a generally slower-growth business, $95 seems far too aggressive a price target over the coming 12 months.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F634050%2Foil-gas-refinery-downstreram-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"438\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Chevron: Implied upside of 54%</h3><p>Lastly, at least one Wall Street investment bank is counting on a gusher of a year from integrated oil and gas giant <b>Chevron</b> (NYSE:CVX). If the high-end price target of $152 proves accurate, Chevron could gallop higher by 54% over the coming year.</p><p>To state the obvious, Chevron benefits from its integrated operating model. Even though higher crude prices are more favorable given the juicier margin potential of its upstream (drilling and exploration) operations, the company is hedged by controlling petrochemical plants and refineries (downstream operations). When the price of crude declines, the input costs for its downstream operations fall, as well, pushing profitability and margins higher.</p><p>The Chevron growth story also can't be told without making mention of its generally superior balance sheet. Whereas most major oil stocks are weighed down by debt, Chevron's debt-to-equity of 34% is considerably lower than many of its peers. When combined with aggressive capital expenditure reductions in the near-term, Chevron looks to have considerably better financial flexibility than other oil majors.</p><p>Ultimately, Chevron's success will be dependent on a continued rebound in the U.S. and global economy. While history does indicate that periods of economic expansion usually last years, Wall Street's high-end price target should, once again, be taken with a grain of salt over the next year.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Dow Stocks With 48% to 58% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Dow Stocks With 48% to 58% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/4-dow-stocks-with-48-to-58-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past 125 years, arguably no stock index has been more widely followed than the Dow Jones Industrial Average (DJINDICES:^DJI). The Dow Jones, which is comprised of 30 profitable, time-tested, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/4-dow-stocks-with-48-to-58-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","DOW":"陶氏化学","INTC":"英特尔","03086":"华夏纳指","CVX":"雪佛龙","WBA":"沃尔格林联合博姿"},"source_url":"https://www.fool.com/investing/2021/07/21/4-dow-stocks-with-48-to-58-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153610463","content_text":"For the past 125 years, arguably no stock index has been more widely followed than the Dow Jones Industrial Average (DJINDICES:^DJI). The Dow Jones, which is comprised of 30 profitable, time-tested, multinational businesses, has become a barometer to gauge the health of the U.S. stock market.It's also home to some serious value, at least according to a handful of Wall Street analysts and investment banks. Wall Street's high-water one-year price target for each of the following four Dow stocks implies upside ranging from 48% to as much as 58%.Image source: Getty Images.Intel: Implied upside of 55%To begin with, at least one Wall Street analyst foresees some significant upside in semiconductor giant Intel (NASDAQ:INTC). According to Robert W. Baird analyst Tristan Gerra, Intel could hit $85 a share, representing upside of 55% over the next year.Among Gerra's chief arguments is that Intel will likely make a big acquisition to shore up its Foundry Services operations. It just so happens that The Wall Street Journal reported last week that Intel is tinkering with the idea of a $30 billion deal to acquire GlobalFoundries, a specialty chip-production company that Advanced Micro Devices spun off back in 2008. Going the acquisition route would emphasize Intel's renewed commitment to keep chip production under its own control, rather than outsource it. Depending on geopolitical or supply and demand concerns, that could become a major competitive edge for Intel.Even though personal-computing chip demand tends to ebb and flow, the future for Intel will likely hinge on data centers. Despite a double-digit percentage decline in data center revenue in the first quarter, demand for storage, processing, and software solutions are only going to increase over the long run as businesses make the shift online and into the cloud.  Intel's road will undoubtedly be bumpy as it spends big bucks on 7nm chip innovation, but it should prove well worth it.An $85 price target may well make sense for Intel, but likely not over the next year.Image source: Getty Images.Walgreen Boots Alliance: Implied upside of 48%Healthcare stocks are also expected to get in on the action. Pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA) has a high-end price target of $68 from analysts at Robert W. Baird. This portends up to 48% upside over the next 12 months.The bullishness surrounding Walgreens likely has to do with the company's ongoing multipoint turnaround plan. By fiscal 2022, Walgreens should be realizing more than $2 billion in annual cost savings, yet at the same time will benefit from hefty investments in digitization. Although online sales only comprise a small portion of total sales, direct-to-consumer is an area of considerable growth opportunity for the generally slow-growing pharmacy chain.Perhaps even more exciting is the partnership between Walgreens Boots Alliance and VillageMD. This duo plans to open as many as 700 full-service clinics (co-located in Walgreens' stores) in more than 30 markets throughout the United States by mid-decade.  Whereas most in-store clinics cater to vaccines or a sniffle, doctor-led full-service practices inside Walgreens have the potential to facilitate repeat business and drive patients right to Walgreens' high-margin pharmacy.As a shareholder, I'm enthusiastic about Walgreens' future. But I suspect it'll take longer than 12 months to reach $68.Image source: Getty Images.Dow Inc.: Implied upside of 58%When it comes to Dow stocks with supercharged return potential, chemicals company Dow Inc. (NYSE:DOW) takes the cake. If the Street-high price target of $95 were to come to fruition, Dow would return 58% for its shareholders over the coming year.The biggest growth driver for Dow is going to be a continued U.S. and global recovery (Dow has a manufacturing presence in 31 countries). If economic activity continues to pick up, not only will the company recognize strong demand for its packaging, specialty plastics, performance materials, and coatings, but this demand will actually improve pricing power for Dow's material solutions. The first quarter saw demand and pricing power improve across all operating segments.Beyond just growing demand, Dow is taking other actions to improve its bottom line. The company has invested aggressively in digitization, while at the same time restructuring its operations to eventually reduce costs by approximately $300 million on an annual basis. Perhaps most important, capacity expansion for its material solutions will allow Dow to meet increased demand as the U.S. and global economy heat up.The bottom line is that Dow is a solid cyclical operating model that'll deliver incremental profit improvements in the years that lie ahead. But as a generally slower-growth business, $95 seems far too aggressive a price target over the coming 12 months.Image source: Getty Images.Chevron: Implied upside of 54%Lastly, at least one Wall Street investment bank is counting on a gusher of a year from integrated oil and gas giant Chevron (NYSE:CVX). If the high-end price target of $152 proves accurate, Chevron could gallop higher by 54% over the coming year.To state the obvious, Chevron benefits from its integrated operating model. Even though higher crude prices are more favorable given the juicier margin potential of its upstream (drilling and exploration) operations, the company is hedged by controlling petrochemical plants and refineries (downstream operations). When the price of crude declines, the input costs for its downstream operations fall, as well, pushing profitability and margins higher.The Chevron growth story also can't be told without making mention of its generally superior balance sheet. Whereas most major oil stocks are weighed down by debt, Chevron's debt-to-equity of 34% is considerably lower than many of its peers. When combined with aggressive capital expenditure reductions in the near-term, Chevron looks to have considerably better financial flexibility than other oil majors.Ultimately, Chevron's success will be dependent on a continued rebound in the U.S. and global economy. While history does indicate that periods of economic expansion usually last years, Wall Street's high-end price target should, once again, be taken with a grain of salt over the next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":63,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9022257989,"gmtCreate":1653535354041,"gmtModify":1676535300552,"author":{"id":"3563679013796521","authorId":"3563679013796521","name":"美股社区","avatar":"https://community-static.tradeup.com/news/9760bfc44d79d203d95bf2625cbe526b","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Strong]&nbsp;","listText":"<a href=\"https://ttm.financial/S/NXPI\">$NXP Semiconductors NV(NXPI)$</a>[Strong]&nbsp;","text":"$NXP Semiconductors NV(NXPI)$[Strong]","images":[{"img":"https://community-static.tradeup.com/news/a250be0f17514cd6088b7266cca77b6f","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9022257989","isVote":1,"tweetType":1,"viewCount":200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}